The goal of Dr. Vivienne Rebel's laboratory is to understand the nature of the molecular
events that lead to the development of Myelodysplastic Syndrome
(MDS). The incidence of MDS in children is low (~ 4 / million per
year), however, after chemotherapeutic treatment as many as 2-6% will
develop MDS, with a median survival of only 13 months! Thus, MDS is a
serious and common side-effect of anti-cancer treatment, one for which
there are currently very few options of effective treatments.
Dong Q, Wang D, Bandyopadhyay A, Gao H, Gorena KM, Hildreth K, Rebel VI, Walter CA, Huang C, Sun LZ. Mammospheres from murine mammary stem cell-enriched basal cells: clonal characteristics and repopulating potential. Stem Cell Res. 2013 May;10(3):396-404.
Kim TM, Rebel VI, Hasty P. Defining a genotoxic profile with mouse embryonic stem cells. Exp Biol Med (Maywood). 2013 Mar;238(3):285-93.
Zhou T, Hasty P, Walter CA, Bishop AJ, Scott LM, Rebel VI. Myelodysplastic syndrome: an inability to appropriately respond to damaged DNA? Exp Hematol. 2013 Aug;41(8):665-74.
Scott LM, Rebel VI. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J Natl Cancer Inst. 2013 Oct 16;105(20):1540-9.
Harris SE, MacDougall M, Horn D, Woodruff K, Zimmer SN, Rebel VI,
Fajardo R, Feng JQ, Gluhak-Heinrich J, Harris MA, Abboud Werner S. Meox2Cre-mediated disruption of CSF-1 leads to osteopetrosis and osteocyte defects. Bone. 2012 Jan;50(1):42-53.